NCT00756990
Completed
Not Applicable
Depot Naltrexone Treatment of Opioid Dependent Parolees
Overview
- Phase
- Not Applicable
- Intervention
- Depot Naltrexone
- Conditions
- Opioid Dependence
- Sponsor
- University of Pennsylvania
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- UDS results
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This is an investigation involving the use of a long-acting, injectable form (depot) of naltrexone as a treatment for persons who have a history of opioid dependence, with up to 40 on parole/probation and 20 non-parolees. The test is a pilot study of up to 60 subjects treated with 6 months of depot naltrexone plus Psychosocial Treatment .
Detailed Description
This is a two phase study. Phase 1 is complete and phase 2 is not yet recruiting.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Single group
Depot Naltrexone
Intervention: Depot Naltrexone
Outcomes
Primary Outcomes
UDS results
Time Frame: 6 months
Secondary Outcomes
- Treatment completion(6 months)
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Naltrexone for Overdose PreventionOverdose AccidentalNCT06633900University of California, San Francisco100
Completed
Phase 1
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice PopulationsHIVAIDSOpioid DependenceDrug DependenceNCT01246401Yale University151
Withdrawn
Not Applicable
Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).Drug DependenceNCT00675532Yale University
Withdrawn
Phase 4
In Hospital IM Naltrexone: A Pilot StudyAlcohol Use DisorderNCT05087771University of Colorado, Denver
Completed
Phase 4
Extended-release Naltrexone for Alcohol Dependence in Primary CareAlcohol DependenceNCT00620750NYU Langone Health72